Drugs / Proteasome siRNA and tumor antigen RNA-transfected dendritic cells
Proteasome siRNA and tumor antigen RNA-transfected dendritic cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00672542 | Jan 2008 → Mar 2013 | metastatic melanoma | Scott Pruitt | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Proteasome siRNA and tumor antigen RNA-transfected dendritic cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00672542 ↗ |
| Modality | Cell therapy | “mature autologous dendritic cells” NCT00672542 ↗ |
| Route | Other | “The vaccine will be administered by intradermal injection in the extremities.” NCT00672542 ↗ |